Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Burris, III, Howard A."" wg kryterium: Autor


Tytuł:
A randomized phase II study of metronomic cyclophosphamide and methotrexate (CM) with or without bevacizumab in patients with advanced breast cancer
Autorzy:
Mayer, Erica L.
Tayob, Nabihah
Ren, Siyang
Savoie, Jennifer J.
Spigel, David R.Aff1, Aff2
Burris, III, Howard A.Aff1, Aff2
Ryan, Paula D.Aff1, Aff3
Harris, Lyndsay N.Aff1, Aff4
Winer, Eric P.Aff1, Aff5
Burstein, Harold J.Aff1, IDs10549023071679_cor10
Pokaż więcej
Źródło:
Breast Cancer Research and Treatment. 204(1):123-132
Czasopismo naukowe
Tytuł:
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Autorzy:
Thompson, Alexander
Danta, Mark
Poursoltan, Pirooz
Kiberu, Andrew
Chittajallu, Renuka
Sood, Siddarth
Stauber, Rudolf
Pinter, Matthias
Peck-Radosavljevic, Markus
Decaestecker, Jochen
Cuyle, Pieter-Jan
Verset, Gontran
Van Vlierberghe, Hans
De Azevedo, Sergio
Andrade, Livia
Cunha Júnior, Ademar
Faria, Luiza
Yen, Cheng Tzu
Colli, Leandro
Asselah, Jamil
Kavan, Petr
Marquez, Vladimir
Brahmania, Mayur
Li, Qiang
Xing, Baocai
Guo, Yabing
Chen, Zhendong
Zhao, Haitao
Peng, Tao
Wang, Liming
Wang, Lu
Liu, Hongming
Wu, Feixiang
Qin, Lunxiu
Zheng, Qichang
Ying, Jieer
Li, Haitao
Wen, Tianfu
Qin, Shukui
Wen, Xiaoyu
Liu, Yunpeng
Chen, Minshan
Wang, Boqing
Bai, Yuxian
He, Yifu
Zhao, Hong
Zhou, Dong
Dai, Chaoliu
Teng, Gaojun
Cui, Shuzhong
Gao, Yi
Zhang, Xizhi
Lu, Zheng
Yin, Tao
Ding, Youming
Jia, Weidong
Xia, Yongxiang
Sun, Beicheng
Xia, Qiang
Yuan, Yufeng
Sun, Huichuan
Shi, Xuetao
Guzmán, Adrián
Corrales, Luis
Kral, Zdenek
Priester, Peter
Kubala, Eugen
Blanc, Jean Frederic
Bourliere, Marc
Peron, Jean Marie
Borg, Christophe
Bronowicki, Jean-Pierre
Ganne, Nathalie
Decaens, Thomas
Uguen, Thomas
Heurgue, Alexandra
Trojan, Joerg
Gonzalez-Carmona, Maria Angeles
Roderburg, Christoph
Ettrich, Thomas
Schotten, Clemens
Kandulski, Arne
Yau, Thomas
Chan, Lam
Scartozzi, Mario
Masi, Gianluca
Fanello, Silvia
Battezzati, Pier Maria
Leonardi, Francesco
Ghidini, Michele
Numata, Kazushi
Morimoto, Manabu
Hidaka, Hisashi
Tsuchiya, Kaoru
Yamashita, Tatsuya
Kato, Naoya
Kudo, Masatoshi
Hagihara, Atsushi
Koga, Hironori
Arakawa, Tomohiro
Nakamura, Ikuo
Kawamura, Yusuke
Kawaoka, Tomokazu
Shimada, Mitsuo
Hasegawa, Kiyoshi
Marusawa, Hiroyuki
Nakamura, Shinchiro
Hiraoka, Atsushi
Hayashi, Hiromitsu
Takeda, Shin
Lee, Han Chu
Paik, Seung Woon
Kim, Do Young
Lee, Jung Il
Jeong, Sook-Hyang
Kim, Won
Tak, Won Young
Heo, Jeong
Kim, Hyeyeong
Chon, Hong Jae
Cheong, Jaeyoun
Yoon, Seung Kew
Yoon, Jung-Hwan
Villalobos, Ricardo
Martinez Rodriguez, Jorge Luis
Oyervides Juarez, Victor
Hernández, Carlos Alberto
Klumpen, Heinz-Josef
de Vos-Geelen, Judith
Gane, Edward
Montenegro, Paola
Torres Mattos, Cesar
Janczewska, Ewa
Kawecki, Maciej
Nowakowska-Zajdel, Ewa
Fedenko, Alexander
Granov, Dmitrii
Alyasova, Anna
Sekacheva, Marina
Ledin, Evgeny
Samol, Jens
Toh, Han Chong
Calvo Campos, Mariona
Gomez Martin, Carlos
Lopez Lopez, Carlos
Muñoz Martin, Andres Jesus
Calleja Panero, Jose Luis
Montero Alvarez, Jose Luis
Reig Monzón, Maria
Delgado Mingorance, Ignacio
Minguez Rosique, Beatriz
Cheng, Ann Lii
Huang, Yi-Hsiang
Lin, Shi-Ming
Huang, Jee-Fu
Yu, Ming-Lung
Su, Wei-Wen
Korphaisarn, Krittiya
Maneenil, Kunlatida
Samdaengpan, Chayanee
Tharavichitkul, Ekkapong
Ozguroglu, Mustafa
Kose, Fatih
Harputluoglu, Hakan
Buchschacher, Gary
Thuluvath, Paul
Xiong, Henry
Patel, Mital
Gold, Philip
Li, Daneng
Brooks, Gabriel
Masood, Ashiq
Patel, Reema
George, Ben
Salgia, Reena
Manji, Gulam
Crow, Mary
Kaseb, Ahmed
Dugan, Matthew
Kadakia, Kunal
Kardosh, Adel
Gibbs, John
Shah, Ashesh
Burris III, Howard
Hsiehchen, David
Cheng, Ann-Lii
Pokaż więcej
Źródło:
In The Lancet 18-24 November 2023 402(10415):1835-1847
Czasopismo naukowe
Tytuł:
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease
Autorzy:
Schmid, PeterAff1, IDs1305802301649w_cor1
Cortes, JavierAff2, Aff3
Joaquim, Ana
Jañez, Noelia Martínez
Morales, Serafín
Díaz-Redondo, Tamara
Blau, Sibel
Neven, Patrick
Lemieux, Julie
García-Sáenz, José Ángel
Hart, Lowell
Biyukov, Tsvetan
Baktash, Navid
Massey, Dan
Burris, III, Howard A.
Rugo, Hope S.
Pokaż więcej
Źródło:
Breast Cancer Research. 25(1)
Czasopismo naukowe
Tytuł:
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Autorzy:
Qin, Shukui
Chen, Minshan
Cheng, Ann-Lii
Kaseb, Ahmed O
Kudo, Masatoshi
Lee, Han Chu
Yopp, Adam C
Zhou, Jian
Wang, Lu
Wen, Xiaoyu
Heo, Jeong
Tak, Won Young
Nakamura, Shinichiro
Numata, Kazushi
Uguen, Thomas
Hsiehchen, David
Cha, Edward
Hack, Stephen P
Lian, Qinshu
Ma, Ning
Spahn, Jessica H
Wang, Yulei
Wu, Chun
Chow, Pierce K H
Thompson, Alexander
Danta, Mark
Poursoltan, Pirooz
Kiberu, Andrew
Chittajallu, Renuka
Sood, Siddarth
Stauber, Rudolf
Pinter, Matthias
Peck-Radosavljevic, Markus
Decaestecker, Jochen
Cuyle, Pieter-Jan
Verset, Gontran
Van Vlierberghe, Hans
De Azevedo, Sergio
Andrade, Livia
Cunha Júnior, Ademar
Faria, Luiza
Yen, Cheng Tzu
Colli, Leandro
Asselah, Jamil
Kavan, Petr
Marquez, Vladimir
Brahmania, Mayur
Li, Qiang
Xing, Baocai
Guo, Yabing
Chen, Zhendong
Zhao, Haitao
Peng, Tao
Wang, Liming
Wang, Lu
Liu, Hongming
Wu, Feixiang
Qin, Lunxiu
Zheng, Qichang
Ying, Jieer
Li, Haitao
Wen, Tianfu
Qin, Shukui
Wen, Xiaoyu
Liu, Yunpeng
Chen, Minshan
Wang, Boqing
Bai, Yuxian
He, Yifu
Zhao, Hong
Zhou, Dong
Dai, Chaoliu
Teng, Gaojun
Cui, Shuzhong
Gao, Yi
Zhang, Xizhi
Lu, Zheng
Yin, Tao
Ding, Youming
Jia, Weidong
Xia, Yongxiang
Sun, Beicheng
Xia, Qiang
Yuan, Yufeng
Sun, Huichuan
Shi, Xuetao
Guzmán, Adrián
Corrales, Luis
Kral, Zdenek
Priester, Peter
Kubala, Eugen
Blanc, Jean Frederic
Bourliere, Marc
Peron, Jean Marie
Borg, Christophe
Bronowicki, Jean-Pierre
Ganne, Nathalie
Decaens, Thomas
Uguen, Thomas
Heurgue, Alexandra
Trojan, Joerg
Gonzalez-Carmona, Maria Angeles
Roderburg, Christoph
Ettrich, Thomas
Schotten, Clemens
Kandulski, Arne
Yau, Thomas
Chan, Lam
Scartozzi, Mario
Masi, Gianluca
Fanello, Silvia
Battezzati, Pier Maria
Leonardi, Francesco
Ghidini, Michele
Numata, Kazushi
Morimoto, Manabu
Hidaka, Hisashi
Tsuchiya, Kaoru
Yamashita, Tatsuya
Kato, Naoya
Kudo, Masatoshi
Hagihara, Atsushi
Koga, Hironori
Arakawa, Tomohiro
Nakamura, Ikuo
Kawamura, Yusuke
Kawaoka, Tomokazu
Shimada, Mitsuo
Hasegawa, Kiyoshi
Marusawa, Hiroyuki
Nakamura, Shinchiro
Hiraoka, Atsushi
Hayashi, Hiromitsu
Takeda, Shin
Lee, Han Chu
Paik, Seung Woon
Kim, Do Young
Lee, Jung Il
Jeong, Sook-Hyang
Kim, Won
Tak, Won Young
Heo, Jeong
Kim, Hyeyeong
Chon, Hong Jae
Cheong, Jaeyoun
Yoon, Seung Kew
Yoon, Jung-Hwan
Villalobos, Ricardo
Martinez Rodriguez, Jorge Luis
Oyervides Juarez, Victor
Hernández, Carlos Alberto
Klumpen, Heinz-Josef
de Vos-Geelen, Judith
Gane, Edward
Montenegro, Paola
Torres Mattos, Cesar
Janczewska, Ewa
Kawecki, Maciej
Nowakowska-Zajdel, Ewa
Fedenko, Alexander
Granov, Dmitrii
Alyasova, Anna
Sekacheva, Marina
Ledin, Evgeny
Samol, Jens
Toh, Han Chong
Calvo Campos, Mariona
Gomez Martin, Carlos
Lopez Lopez, Carlos
Muñoz Martin, Andres Jesus
Calleja Panero, Jose Luis
Montero Alvarez, Jose Luis
Reig Monzón, Maria
Delgado Mingorance, Ignacio
Minguez Rosique, Beatriz
Cheng, Ann Lii
Huang, Yi-Hsiang
Lin, Shi-Ming
Huang, Jee-Fu
Yu, Ming-Lung
Su, Wei-Wen
Korphaisarn, Krittiya
Maneenil, Kunlatida
Samdaengpan, Chayanee
Tharavichitkul, Ekkapong
Ozguroglu, Mustafa
Kose, Fatih
Harputluoglu, Hakan
Buchschacher, Gary
Thuluvath, Paul
Xiong, Henry
Patel, Mital
Gold, Philip
Li, Daneng
Brooks, Gabriel
Masood, Ashiq
Patel, Reema
George, Ben
Salgia, Reena
Manji, Gulam
Crow, Mary
Kaseb, Ahmed
Dugan, Matthew
Kadakia, Kunal
Kardosh, Adel
Gibbs, John
Shah, Ashesh
Burris III, Howard
Hsiehchen, David
Pokaż więcej
Źródło:
The Lancet; November 2023, Vol. 402 Issue: 10415 p1835-1847, 13p
Periodyk
Tytuł:
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
Autorzy:
Hainsworth, John D.
Becker, Kevin P.
Mekhail, Tarek
Chowdhary, Sajeel A.
Eakle, Janice Faulkner
Wright, David
Langdon, Robert M.
Yost, Kathleen J.
Padula, Gilbert Darin Anthony
West-Osterfield, Kimberly
Scarberry, Meredith
Shaifer, Candice A.
Shastry, Mythili
Burris, III, Howard A.
Shih, Kent
Pokaż więcej
Źródło:
Journal of Neuro-Oncology. 144(2):303-311
Czasopismo naukowe
Tytuł:
A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors
Autorzy:
Aghajanian, CarolAff1, Aff2, IDs106370180591z_cor1
Bell-McGuinn, Katherine M.Aff1, Aff2, Aff3
Burris, III, Howard A.Aff4, Aff5
Siu, Lillian L.
Stayner, Lee-Ann
Wheler, Jennifer J.
Hong, David S.
Kurkjian, CarlaAff4, Aff8
Pant, ShubhamAff4, Aff8
Santiago-Walker, AdemiAff9, Aff10
Gauvin, Jennifer L.Aff9, Aff11
Antal, Joyce M.Aff9, Aff12
Opalinska, Joanna B.Aff9, Aff13
Morris, Shannon R.Aff9, Aff12
Infante, Jeffrey R.Aff4, Aff5
Pokaż więcej
Źródło:
Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies. 36(6):1016-1025
Czasopismo naukowe
Tytuł:
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Autorzy:
Perez, Edith A.
de Haas, Sanne Lysbet
Eiermann, Wolfgang
Barrios, Carlos H.
Toi, Masakazu
Im, Young-Hyuck
Conte, Pier Franco
Martin, Miguel
Pienkowski, Tadeusz
Pivot, Xavier B.
Burris, III, Howard A.
Stanzel, Sven
Patre, Monika
Ellis, Paul Anthony
Pokaż więcej
Źródło:
BMC Cancer. 19(1)
Czasopismo naukowe
Tytuł:
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer
Autorzy:
Perez, Edith A.
de Haas, Sanne Lysbet
Eiermann, Wolfgang
Barrios, Carlos H.
Toi, Masakazu
Im, Young-Hyuck
Conte, Pier Franco
Martin, Miguel
Pienkowski, Tadeusz
Pivot, Xavier B.
Burris, III, Howard A.
Stanzel, Sven
Patre, Monika
Ellis, Paul Anthony
Pokaż więcej
Źródło:
BMC Cancer. 19(1)
Czasopismo naukowe
Czasopismo naukowe
Tytuł:
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumors
Autorzy:
Infante, Jeffrey R.
Mendelson, David S.
Burris, III, Howard A.
Bendell, Johanna C.
Tolcher, Anthony W.
Gordon, Michael S.
Gillenwater, Heidi H.
Arastu-Kapur, Shirin
Wong, Hansen L.
Papadopoulos, Kyriakos P.
Pokaż więcej
Źródło:
Investigational New Drugs: The Journal of New Anticancer Agents. April 2016 34(2):216-224
Czasopismo naukowe
Tytuł:
A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin
Autorzy:
Gray, Jhanelle E.
Infante, Jeffrey R.
Brail, Les H.
Simon, George R.
Cooksey, Jennifer F.
Jones, Suzanne F.
Farrington, Daphne L.
Yeo, Adeline
Jackson, Kimberley A.
Chow, Kay H.
Zamek-Gliszczynski, Maciej J.
Burris, III, Howard A.
Pokaż więcej
Źródło:
Investigational New Drugs: The Journal of New Anticancer Agents. December 2015 33(6):1187-1196
Czasopismo naukowe
Tytuł:
A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response with the 21-gene recurrence score
Autorzy:
Yardley, Denise A.
Peacock, Nancy W.
Shastry, Mythili
Burris, III, Howard A.
Bechhold, Rebecca G.
Hendricks, Carolyn B.
Yoshizawa, Carl N.
Sing, Amy P.
Hainsworth, John D.
Pokaż więcej
Źródło:
Breast Cancer Research and Treatment. November 2015 154(2):299-308
Czasopismo naukowe
Tytuł:
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute
Autorzy:
Yardley, Denise A.
Bosserman, Linda D.
O’Shaughnessy, Joyce A.
Harwin, William N.
Morgan, Susan K.
Priego, Victor M.
Peacock, Nancy W.
Bass, J. David
Burris III, Howard A.
Hainsworth, John D.
Pokaż więcej
Źródło:
Breast Cancer Research and Treatment. November 2015 154(1):89-97
Czasopismo naukowe
Tytuł:
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
Autorzy:
Bendell, Johanna C.Aff1, Aff2, Aff4, IDs1063701502186_cor1
Kurkjian, CarlaAff1, Aff3
Infante, Jeffrey R.Aff1, Aff2
Bauer, Todd M.Aff1, Aff2
Burris, III, Howard A.Aff1, Aff2
Greco, F. AnthonyAff1, Aff2
Shih, Kent C.Aff1, Aff2
Thompson, Dana S.Aff1, Aff2
Lane, Cassie M.
Finney, Lindsey H.
Jones, Suzanne F.
Pokaż więcej
Źródło:
Investigational New Drugs: The Journal of New Anticancer Agents. 33(2):463-471
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies